testosterone cypionate

Also found in: Dictionary, Thesaurus, Encyclopedia.
Related to testosterone cypionate: Testosterone propionate, Testosterone enanthate

testosterone cypionate

(tess-toss-te-rone sip-eye-oh-nate) ,


(trade name)


Therapeutic: hormones
Pharmacologic: androgens
Pregnancy Category: X


Hypogonadism in androgen-deficient men.


Responsible for the normal growth and development of male sex organs.
Maintenance of male secondary sex characteristics:
  • Growth and maturation of the prostate, seminal vesicles, penis, scrotum,
  • Development of male hair distribution,
  • Vocal cord thickening,
  • Alterations in body musculature and fat distribution.

Therapeutic effects

Correction of hormone deficiency in male hypogonadism.


Absorption: Well absorbed from IM sites; absorbed slowly.
Distribution: Crosses the placenta.
Protein Binding: 98%.
Metabolism and Excretion: Metabolized by the liver; 90% eliminated in urine as metabolites.
Half-life: 8 days.

Time/action profile (androgenic effects†)

IMunknownunknown2–4 wk
†Response is highly variable among individuals; may take months


Contraindicated in: Hypersensitivity; Obstetric: Pregnancy and lactation; Male patients with breast or prostate cancer; Severe liver, renal, or cardiac disease; Patients with known hypersensitivity to benzyl alcohol.
Use Cautiously in: Benign prostatic hyperplasia; Hypercalcemia; Geriatric patients (↑ risk of prostatic hyperplasia/carcinoma); Males <12 yr (safety and effectiveness not established).

Adverse Reactions/Side Effects

Ear, Eye, Nose, Throat

  • deepening of voice (most frequent)


  • edema (most frequent)


  • cholestatic jaundice
  • drug-induced hepatitis
  • liver function test elevation
  • nausea
  • vomiting


  • change in libido (most frequent)
  • erectile dysfunction (most frequent)
  • priapism (most frequent)
  • prostatic enlargement


  • gynecomastia (most frequent)
  • hirsutism (most frequent)
  • oligospermia (most frequent)
  • hypercholesterolemia

Fluid and Electrolyte

  • hypercalcemia
  • hyperkalemia
  • hyperphosphatemia


  • male pattern baldness


  • pain at injection site


Drug-Drug interaction

May ↑ action of warfarin, oral hypoglycemic agents, andinsulin.Concurrent use with corticosteroids may ↑ risk of edema formation.


Intramuscular (Adults) Replacement therapy–50–400 mg every 2–4 wk.

Availability (generic available)

Injection (in oil): 100 mg/mL in 10-mL vials, 200 mg/mL in 1- and 10-mL vials

Nursing implications

Nursing assessment

  • Monitor intake and output ratios, weigh patient twice weekly, and assess patient for edema. Report significant changes indicative of fluid retention.
  • Men: Monitor for precocious puberty in boys (acne, darkening of skin, development of male secondary sex characteristics—increase in penis size, frequent erections, growth of body hair). Bone age determinations should be measured every 6 mo to determine rate of bone maturation and effects on epiphyseal closure.
    • Monitor for breast enlargement, persistent erections, and increased urge to urinate in men. Monitor for difficulty urinating in elderly men, because prostate enlargement may occur.
  • Lab Test Considerations: Monitor hemoglobin and hematocrit periodically during therapy; may cause polycythemia.
    • Monitor hepatic function tests and serum cholesterol levels periodically during therapy. May ↑ serum AST, ALT, and bilirubin, ↑ cholesterol levels, and suppress clotting factors II, V, VII, and X.
    • Monitor blood glucose closely in patients with diabetes who are receiving oral hypoglycemic agents or insulin.
    • Monitor serum sodium, chloride, potassium, and phosphate concentrations (may be ↑).

Potential Nursing Diagnoses

Sexual dysfunction (Indications,  Side Effects)


  • Range-of-motion exercises should be done with all bedridden patients to prevent mobilization of calcium from the bone.
  • Intramuscular: Administer IM deep into gluteal muscle. Crystals may form when vials are stored at low temperatures; warming and shaking the vial will redissolve crystals. Use of a wet syringe or needle may cause solution to become cloudy but will not affect its potency.

Patient/Family Teaching

  • Advise patient to report the following signs and symptoms promptly: priapism (sustained and often painful erections), difficulty urinating, gynecomastia, edema (unexpected weight gain, swelling of feet), hepatitis (yellowing of skin or eyes and abdominal pain), or unusual bleeding or bruising.
    • Explain rationale for prohibiting use of testosterone for increasing athletic performance. Testosterone is neither safe nor effective for this use and has a potential risk of serious side effects.
    • Advise diabetic patients to monitor blood closely for alterations in blood glucose concentrations.
    • Emphasize the importance of regular follow-up physical exams, lab tests, and x-ray exams to monitor progress.
    • Radiologic bone age determinations should be evaluated every 6 mo in prepubertal children to determine rate of bone maturation and effects on epiphyseal centers.

Evaluation/Desired Outcomes

  • Resolution of the signs of androgen deficiency without side effects. Therapy is usually limited to 3–6 mo followed by bone growth or maturation determinations.

testosterone cypionate

a long-acting form of testosterone. Also called testosterone cyclopentylpropionate.
References in periodicals archive ?
The injectable drugs identified so far include: baclofen, betamethasone, phentolamine mesylate /papaverine (Bimix 30:1), clonidine, estradiol, hydromorphone, fentanyl, methylprednisole acetate, morphine sulfate/bupivacaine, papaverine, papaverine / phentolamine mesylate /prostaglandin (Super Trimix), testosterone cypionate, and testosterone / estradiol.
1997) using a double-blind placebo controlled design, gave older, hypogonadal men bi-weekly injections of 200mg testosterone cypionate.
of pure testosterone cypionate, I would not get a 200 percent elevation an hour - and you really think you can get this from one 100 mg.
Each subject received two weekly placebo doses of cottonseed oil, the vehicle for testosterone cypionate (TC).
Although one study found testosterone propionate effective in conditioned taste aversion (CTA) learning in female mice (Peeters, Smets, & Broekkamp, 1992), two separate studies from our laboratory, one utilizing testosterone propionate in male and female mice (Miele, Rosellini, & Svare, 1988), the other testosterone cypionate and nandrolone in male mice (Ganesan, Rosellini, & Svare, 1993), demonstrated that these androgens were ineffective in producing a CTA.